U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07285304) titled 'A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis' on Nov. 24.
Brief Summary: A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Hyperphosphatemia Patients on Hemodialysis
Intervention:
DRUG: TS-172
oral administration of TS-172 20~60 mg/day
Recruitment Status: RECRUITING
Sponsor: Taisho Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....